TY - JOUR
T1 - A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects
AU - Cecilia, D.
AU - Kleeberger, C.
AU - Muñoz, A.
AU - Giorgi, Janis V.
AU - Zolla-Pazner, Susan
N1 - Funding Information:
Financial support: The MACS is funded by the National Institute of Allergy and Infectious Diseases with additional supplemental funding from the National Cancer Institute (U01-AI-35042, M01-RR-00052 (GCRC), U01-AI-35043, U01-AI-37984, U01-AI-35039, U01-AI-35040, U01-AI-37613, and U01-AI-35041).
Funding Information:
At the Veterans Affairs Medical Center and New York University, work was funded by the National Institutes of Health (R01-AI-32424, R01-AI/ HL-36085, R01-HL-59725, and P30-AI-27742, which supports the Immunology and Flow Cytometry Cores of the NYU Center for AIDS Research) and the Department of Veterans Affairs (Research Center for AIDS and HIV Infection and Merit Review funding).
PY - 1999
Y1 - 1999
N2 - Sera from human immunodeficiency virus-1-infected participants in the Multicenter AIDS Cohort Study were tested to assess the association between serum neutralizing antibodies (NAbs) and disease progression. Each of 14 pairs, retrospectively matched for age, sex, race, and CD4+ lymphocyte numbers early in the study, consisted of a rapid progressor (RP) who developed AIDS and a long-term nonprogressor (LTNP) who remained asymptomatic. Serum samples were drawn early, when all participants were asymptomatic, and late, when the RPs had developed clinical AIDS. The LTNPs and RPs had similar levels of NAbs against primary isolates at the early time point, indicating that NAb levels are not predictive of disease progression; at the late time point, the LTNPs had significantly higher titers because of an increase in the level of serum NAbs in the LTNPs and/or a decrease in the NAbs in the RPs. The patterns of neutralizing activity over time suggest that changes in effective NAbs against different viruses do not occur in parallel.
AB - Sera from human immunodeficiency virus-1-infected participants in the Multicenter AIDS Cohort Study were tested to assess the association between serum neutralizing antibodies (NAbs) and disease progression. Each of 14 pairs, retrospectively matched for age, sex, race, and CD4+ lymphocyte numbers early in the study, consisted of a rapid progressor (RP) who developed AIDS and a long-term nonprogressor (LTNP) who remained asymptomatic. Serum samples were drawn early, when all participants were asymptomatic, and late, when the RPs had developed clinical AIDS. The LTNPs and RPs had similar levels of NAbs against primary isolates at the early time point, indicating that NAb levels are not predictive of disease progression; at the late time point, the LTNPs had significantly higher titers because of an increase in the level of serum NAbs in the LTNPs and/or a decrease in the NAbs in the RPs. The patterns of neutralizing activity over time suggest that changes in effective NAbs against different viruses do not occur in parallel.
UR - http://www.scopus.com/inward/record.url?scp=0033032134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033032134&partnerID=8YFLogxK
U2 - 10.1086/314773
DO - 10.1086/314773
M3 - Article
C2 - 10228056
AN - SCOPUS:0033032134
SN - 0022-1899
VL - 179
SP - 1365
EP - 1374
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -